[Approach of menopause in women at risk for breast cancer].
The small but significant increase in risk of discovering breast cancer in women with hormone replacement therapy and the recent discussion of coronary benefit of this treatment have led many authors to insist on the necessity to evaluate the benefit/risks ratio before administration. This evaluation is particularly important for women that are already at high risk of breast cancer because of some genetic predisposition, family history or some benign breast diseases. In these cases, it is important to evaluate the absolute risk of breast cancer, to define the patient's needs more precisely, to specify menopausal symptoms; it is also important to evaluate the risk of osteoporosis, to review the various therapeutic possibilities, which are not only estrogen/progestin treatments (there are alternative treatments), and to give the patients honest information. Before obtaining the results of current trials, we are proposing here a pragmatic attitude and a decision algorithm to adopt a therapeutic attitude more easily which will be decided together by both patients and their physicians.
This
P
P
Service de chirurgie à orientation sénologique, Institut Curie, 75231 Paris, France. pthis@ch-versailles.fr
Cormier
C
C
D001943:Breast Neoplasms / Q000235:genetics; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008593:Menopause; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors
D011372:Progestins